Ucsf

Pharma Mar originally developed Aplidin as a cancer drug, studying its effects in trials with multiple myeloma patients. In 2017, the European Medicines Agency, which regulates drugs in the European Union, refused to approve Aplidin, pointing to side effects experienced by some cancer patients who took it and saying the benefits of the drug did not outweigh the risks. But Pharma Mar successfully challenged the ruling in EU court, vacating the decision, and Australian regulators approved Aplidin for treating multiple myeloma in 2018. … [Read more...] about ‘New weapon’ to kill COVID? UCSF-led team finds drug that could be far more effective than remdesivir